U.S. pharma huge copyright scrapped two experimental weight loss products previous year—a at the time-everyday tablet, lotiglipron, resulting from elevated liver enzymes along with a twice-every day pill, danuglipron, because of strong Uncomfortable side effects—but CEO Albert Bourla